These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Translational potential of allosteric modulators targeting the cannabinoid CB Lu D; Immadi SS; Wu Z; Kendall DA Acta Pharmacol Sin; 2019 Mar; 40(3):324-335. PubMed ID: 30333554 [TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications. Kulkarni AR; Garai S; Janero DR; Thakur GA Methods Enzymol; 2017; 593():281-315. PubMed ID: 28750808 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Garai S; Schaffer PC; Laprairie RB; Janero DR; Pertwee RG; Straiker A; Thakur GA Bioorg Med Chem; 2021 Nov; 50():116421. PubMed ID: 34634617 [TBL] [Abstract][Full Text] [Related]
8. The future of type 1 cannabinoid receptor allosteric ligands. Alaverdashvili M; Laprairie RB Drug Metab Rev; 2018 Feb; 50(1):14-25. PubMed ID: 29355038 [TBL] [Abstract][Full Text] [Related]
9. Assessing Allosteric Modulation of CB Scott CE; Kendall DA Methods Enzymol; 2017; 593():317-342. PubMed ID: 28750809 [TBL] [Abstract][Full Text] [Related]
10. Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling. Jakowiecki J; Abel R; Orzeł U; Pasznik P; Preissner R; Filipek S Molecules; 2021 Apr; 26(9):. PubMed ID: 33922473 [TBL] [Abstract][Full Text] [Related]
11. Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor. Janero DR; Yaddanapudi S; Zvonok N; Subramanian KV; Shukla VG; Stahl E; Zhou L; Hurst D; Wager-Miller J; Bohn LM; Reggio PH; Mackie K; Makriyannis A ACS Chem Neurosci; 2015 Aug; 6(8):1400-10. PubMed ID: 25978068 [TBL] [Abstract][Full Text] [Related]
12. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. Garai S; Leo LM; Szczesniak AM; Hurst DP; Schaffer PC; Zagzoog A; Black T; Deschamps JR; Miess E; Schulz S; Janero DR; Straiker A; Pertwee RG; Abood ME; Kelly MEM; Reggio PH; Laprairie RB; Thakur GA J Med Chem; 2021 Jun; 64(12):8104-8126. PubMed ID: 33826336 [TBL] [Abstract][Full Text] [Related]
13. Modulation of CB1 cannabinoid receptor by allosteric ligands: Pharmacology and therapeutic opportunities. Khurana L; Mackie K; Piomelli D; Kendall DA Neuropharmacology; 2017 Sep; 124():3-12. PubMed ID: 28527758 [TBL] [Abstract][Full Text] [Related]
14. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains. Janero DR; Korde A; Makriyannis A Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804 [TBL] [Abstract][Full Text] [Related]
15. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Schaffer PC; Kulkarni PM; Janero DR; Thakur GA Bioorg Med Chem; 2020 Nov; 28(21):115727. PubMed ID: 33065437 [TBL] [Abstract][Full Text] [Related]
16. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery. Gado F; Meini S; Bertini S; Digiacomo M; Macchia M; Manera C Future Med Chem; 2019 Aug; 11(15):2019-2037. PubMed ID: 31517528 [TBL] [Abstract][Full Text] [Related]
17. Allosteric modulators of cannabinoid receptor 1: developing compounds for improved specificity. Dopart R; Lu D; Lichtman AH; Kendall DA Drug Metab Rev; 2018 Feb; 50(1):3-13. PubMed ID: 29355030 [TBL] [Abstract][Full Text] [Related]
18. CB1 Cannabinoid Receptor Signaling and Biased Signaling. Leo LM; Abood ME Molecules; 2021 Sep; 26(17):. PubMed ID: 34500853 [TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-1 receptor (CB1R) blockers as medicines: beyond obesity and cardiometabolic disorders to substance abuse/drug addiction with CB1R neutral antagonists. Janero DR Expert Opin Emerg Drugs; 2012 Mar; 17(1):17-29. PubMed ID: 22335400 [TBL] [Abstract][Full Text] [Related]
20. Structural dynamics and energetics underlying allosteric inactivation of the cannabinoid receptor CB1. Fay JF; Farrens DL Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8469-74. PubMed ID: 26100912 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]